Efficacy, safety and tolerability of TD1414 2 percent cream in impetigo and secondarily infected traumatic lesions (SITL).
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2018
At a glance
- Drugs TD 1414 (Primary) ; Mupirocin
- Indications Bacterial infections; Impetigo; Wound infections
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 10 Mar 2010 Actual end date added to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 10 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Mar 2009 Actual patient number (682) added as reported by ClinicalTrials.gov.